title: Origin of 4-hydroxynonenal incubation-induced inhibition of dopamine transporter and Na+/K+ adenosine triphosphate in rat striatal synaptosomes.
abstract: Previous experiments reported that an incubation of striatal synaptosomes with 4-hydroxynonenal (4-HNE) resulted in an inhibition of dopamine (DA) uptake and Na+/K+ adenosine triphosphate (ATPase) activity. The present work investigated whether theses inhibitions are related to a 4-HNE binding to the DA transporter (DAT) and the Na+/K+ ATPase. The number of specific [125I]-PE21 binding sites on the DAT was significantly reduced after incubation with 4-HNE. The Na+/K+ ATPase activity decrease induced by 4-HNE was partially reversed, in a dose-dependent manner, by veratridine, a pump stimulator agent. Our previous data (Morel, P., Tallineau, C., Pontcharraud, R., Piriou, A. and Huguet, F., Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/K+ ATPase in rat striatal synaptosomes. Neurochem. Int., 33 (1999) 531-540) combining with the data observed in this study suggest that changes in DA uptake in striatal synaptosomes are directly related to 4-HNE binding to the DAT, whereas the decrease in Na+/K+ ATPase activity resulted only partially from 4-HNE binding to the pump and is mainly secondary to membrane lipid disruption.
authors.affiliation: Center for Study and Research on Xenobiotics, College of Medicine and Pharmacy, Poitiers, France. patricia.fleuranceau@schering.de
authors.forename: P
authors.initials: P
authors.lastname: Fleuranceau-Morel
authors.forename: L
authors.initials: L
authors.lastname: Barrier
authors.forename: B
authors.initials: B
authors.lastname: Fauconneau
authors.forename: A
authors.initials: A
authors.lastname: Piriou
authors.forename: F
authors.initials: F
authors.lastname: Huguet
mesh_terms: D000251:Adenosine Triphosphatases / Q000187:drug effects* / Q000378:metabolism; D000444:Aldehyde Dehydrogenase / Q000037:antagonists & inhibitors*; D000447:Aldehydes / Q000494:pharmacology*; D000818:Animals; D002352:Carrier Proteins / Q000187:drug effects* / Q000378:metabolism; D027682:Cation Transport Proteins; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D050483:Dopamine Plasma Membrane Transport Proteins; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D051381:Rats; D017208:Rats, Wistar; D000254:Sodium-Potassium-Exchanging ATPase; D013574:Synaptosomes / Q000187:drug effects* / Q000378:metabolism; D014701:Veratridine / Q000494:pharmacology
chemical_list: D000447:Aldehydes; D002352:Carrier Proteins; D027682:Cation Transport Proteins; D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; C493216:Slc6a3 protein, rat; D014701:Veratridine; D000444:Aldehyde Dehydrogenase; D000251:Adenosine Triphosphatases; C022761:potassium transporting ATPase; C021838:sodium-translocating ATPase; D000254:Sodium-Potassium-Exchanging ATPase; C027576:4-hydroxy-2-nonenal